Brooks Laboratories

Brooks Laboratories EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Brooks Laboratories (BROOKS.NS) as of Oct 18, 2026 is 33.23. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -1,796.27 — a change of -101.85% (higher).

EV/FCF

33.23

YoY

-101.85%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Brooks Laboratories is 2026 33.23 . EV/FCF (Enterprise Value to Free Cash Flow) of Brooks Laboratories was 2025 -1,796.27 . It decreases by -101.85% higher compared to the previous year.

The Brooks Laboratories EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
-33.26 INR
Jan 1, 2020
-16.31 INR
Jan 1, 2021
-171.92 INR
Jan 1, 2022
-2.93 INR
Jan 1, 2023
-11.67 INR
Jan 1, 2024
-17.15 INR
Jan 1, 2025
-1,796.27 INR
Jan 1, 2026
33.23 INR
The Brooks Laboratories EV/FCF history
YEAREV/FCFYoY
33.23-101.85%
-1,796.27+10,370.96%
-17.15+46.99%
-11.67+298.04%
-2.93-98.29%
-171.92+953.78%
-16.31-50.94%
-33.26+103.08%
-16.38-26.68%
-22.34+261.80%
-6.17-24.24%
-8.15-157.25%
14.23—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Brooks Laboratories Stock analysis

What does Brooks Laboratories do? Brooks Laboratories Ltd is a pharmaceutical manufacturing enterprise headquartered in Mumbai, Maharashtra, India, operating within the health care sector under the industry classification of life sciences tools and services. The company maintains a workforce of 296 full-time employees dedicated to its research and development initiatives and production operations. Brooks Laboratories went public on September 2, 2011, listing its shares on the National Stock Exchange of India under the ticker symbol BROOKS.NS and the ISIN INE650L01011. The firm’s primary business activity revolves around the Pharmaceuticals segment, where it focuses on the manufacturing of a diverse range of pharmaceutical dosage forms. These products include injections, tablets, dry syrups, and eye and ear drops, catering to various therapeutic needs. A significant portion of the company’s portfolio consists of products under the Carbapenem category, which includes several specific formulations such as Imipenem combined with Cilastatin in 250mg and 500mg strengths, as well as Meropenem in dosages ranging from 125mg to 1000mg. The Meropenem offerings also include combinations with Sulbactam and Tazobactam, alongside Doripenem in 500mg and 1000mg strengths. In addition to Carbapenems, Brooks Laboratories produces Penicillins available in injection, tablet, and dry syrup forms. The General category of its product line encompasses liquid injections, dry powder injections, and ophthalmic and otic drops. Notable liquid injections include Iron sucrose with a concentration of 100mg/5ml. The company’s manufacturing infrastructure includes plants located in Baddi, Himachal Pradesh. Brooks Laboratories markets its pharmaceutical products both nationally and internationally, supplying to various regulated markets around the world. The company’s operational scope is defined by its commitment to producing high-quality pharmaceuticals that meet international regulatory standards. Through its dedicated team and established manufacturing facilities, Brooks Laboratories continues to serve the global health care market with its extensive range of medicinal products. The firm’s online presence is maintained through its official website, providing further information on its products and services. As a listed entity, the company is subject to the regulatory requirements of the Indian stock markets, ensuring transparency and accountability in its corporate governance and financial reporting. Brooks Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Brooks Laboratories stock

EV/FCF (Enterprise Value to Free Cash Flow) of Brooks Laboratories is 33.23 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Brooks Laboratories changed from -1,796.27 to 33.23, representing a -101.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Brooks Laboratories since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Brooks Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Brooks Laboratories

All Key Metrics — Brooks Laboratories